Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325 · View on ClinicalTrials.gov ↗
Study Summary
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VRDN-003
Study Locations (20)
Florida
- C A Clinical Trial Corp. — Cape Coral
- Herco Medical and Research Center — Coral Gables
- Alfa Medical Research — Davie
- D H Doral Research Center — Doral
- Eye Centers of Florida — Fort Myers
- Sina Medical Center — Homestead
- East Coast Institute for Research, LLC — Jacksonville
- Southern Clinical Research LLC — Miami
- Retreat Medical Research — Miami
- Continental Clinical Research — Miami
- Edward Jenner Research Group LLC — Plantation
- Sarasota Retina Institute — Sarasota
California
- United Medical Research Institute — Inglewood
- Orbital Plastics — Newport Beach
- California Eye Specialists Medical Group INC — Pasadena
- FOMAT Medical Research — Pismo Beach
- Pacific Neuroscience Institute — Santa Monica
- Pacific Neuroscience Institute at Saint John's Physician Partners — Torrance
Arizona
- Catalina Eye Care — Tuscon
Illinois
- Advanced Quality Medical Research — Orland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06812325
The ClinicalTrials.gov registry entry for NCT06812325 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viridian Therapeutics, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Thyroid Eye Disease (TED) appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06812325 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06812325 about?
NCT06812325 is a clinical study titled "A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)". This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
What is the current status of trial NCT06812325?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 321 participants. The study started on 2025-02-03. Estimated completion is 2026-10.
What conditions does trial NCT06812325 study?
This clinical trial studies the following conditions: Thyroid Eye Disease (TED). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06812325?
The interventions under investigation include: Placebo (DRUG), VRDN-003 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06812325?
This trial is sponsored by Viridian Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06812325 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.